Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
291
-
Total 13F shares, excl. options
-
197M
-
Shares change
-
+22M
-
Total reported value, excl. options
-
$1.77B
-
Value change
-
+$205M
-
Put/Call ratio
-
0.59
-
Number of buys
-
163
-
Number of sells
-
-112
-
Price
-
$8.96
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q2 2025
335 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q2 2025.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 291 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 197M shares
of 210M outstanding shares and own 94.04% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (21.4M shares), VANGUARD GROUP INC (20.5M shares), STATE STREET CORP (8.51M shares), Kynam Capital Management, LP (8.46M shares), ALKEON CAPITAL MANAGEMENT LLC (5.71M shares), UBS Group AG (5.61M shares), MORGAN STANLEY (5.33M shares), GEODE CAPITAL MANAGEMENT, LLC (5.05M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (4.69M shares), and Avoro Capital Advisors LLC (4.5M shares).
This table shows the top 291 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.